Theratechnologies Inc. announced the completion of its previously announced plan of arrangement, under which CB Biotechnology, LLC, an affiliate of Future Pak, LLC, has acquired all issued and outstanding common shares of the company. This transaction marks Theratechnologies' transition to private ownership.
Shareholders received US$3.01 per share in cash, plus one contingent value right (CVR) per share, which entitles holders to additional aggregate cash payments of up to US$1.19 per CVR if certain milestones are achieved. The fair market value of each CVR was determined to be US$0.80 as of September 24, 2025.
As a result of the acquisition, Theratechnologies' shares are expected to be delisted from the Toronto Stock Exchange on or about September 26, 2025, and from the Nasdaq Capital Market on or about September 25, 2025. The company will also apply to cease being a reporting issuer under Canadian securities laws and deregister its shares with the U.S. Securities and Exchange Commission.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.